Camille Deguillard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Camille Deguillard has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Armand Mekontso Dessap
AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, Créteil, France
1 shared publication - Athanasios Koutsoukis
Pôle cardiovasculaire imagerie et interventionnel, Clinique les Fontaines, 77000 Melun, France
1 shared publication - Damien Fard
Department of Cardiovascular Medicine, AP-HP, Henri Mondor University Hospital, 94000 Créteil, France
1 shared publication - Laureline Faivre
Department of Cardiovascular Medicine, AP-HP, Henri Mondor University Hospital, 94000 Créteil, France
1 shared publication - Nicolas Mongardon
Service d'anesthésie-réanimation et médecine péri-opératoire, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux Universitaires Henri Mondor, Créteil, France; U955-IMRB, Equipe 03 "Pharmacologie et Technologies pour les Maladies Cardiovasculaires (PROTECT)", Inserm, Univ Paris Est Créteil (UPEC), Ecole nationale vétérinaire d'Alfort (EnvA), Maisons-Alfort, France; GRCT OPTIMA, Université Paris Est Créteil, Faculté de Santé, Créteil, France
1 shared publication - Pascal Lim
Department of Cardiovascular Medicine, AP-HP, Henri Mondor University Hospital, 94000 Créteil, France
1 shared publication
Latest Publications
- Open Access
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3605
Levosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
Randomized studies showed that Dobutamine and Levosimendan have similar impact on outcome but their combination has never been assessed in acute decompensated heart failure (ADHF) with low cardiac output. This is a retrospective, single-center study that included 89 patients (61 ± 15 years) admitted for ADHF requiring inotropic support. The first group consisted of patients treated with dobutamine alone (n = 42). In the second group, levosimendan was administered on top of dobutamine, when the superior vena cava oxygen saturation (ScVO2) remained 60%) was reached in 36% and 32% of patients in the dobutamine and dobutamine-levosimendan group, respectively. After adding levosimendan, 72% of the dobutamine-levosimendan-group reached the ScVO2 target value at dobutamine weaning. At six months, 42 (47%) patients experienced MACE (n = 29 for death). MACE was less frequent in the dobutamine-levosimendan (32%) than in the dobutamine-group (64%, p = 0.003). Independent variables associated with outcome were admission systolic blood pressure and dobutamine-levosimendan strategy (OR = 0.44 (0.23–0.84), p = 0.01). In conclusion, levosimendan added to dobutamine may improve the outcome of ADHF refractory to dobutamine alone.
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3605
Open AccessLevosimendan Plus Dobutamine in Acute Decompensated Heart Failure Refractory to Dobutamine
Randomized studies showed that Dobutamine and Levosimendan have similar impact on outcome but their combination has never been assessed in acute decompensated heart failure (ADHF) with low cardiac output. This is a retrospective, single-center study that included 89 patients (61 ± 15 years) admitted for ADHF requiring inotropic support. The first group consisted of patients treated with dobutamine alone (n = 42). In the second group, levosimendan was administered on top of dobutamine, when the superior vena cava oxygen saturation (ScVO2) remained 60%) was reached in 36% and 32% of patients in the dobutamine and dobutamine-levosimendan group, respectively. After adding levosimendan, 72% of the dobutamine-levosimendan-group reached the ScVO2 target value at dobutamine weaning. At six months, 42 (47%) patients experienced MACE (n = 29 for death). MACE was less frequent in the dobutamine-levosimendan (32%) than in the dobutamine-group (64%, p = 0.003). Independent variables associated with outcome were admission systolic blood pressure and dobutamine-levosimendan strategy (OR = 0.44 (0.23–0.84), p = 0.01). In conclusion, levosimendan added to dobutamine may improve the outcome of ADHF refractory to dobutamine alone.